Chris Colabello’s career was one of baseball’s most unusual late-bloomer stories: after going undrafted out of Division II Assumption University, he spent seven seasons in independent leagues before reaching the majors with the Minnesota Twins in 2013. By 2015, at age 31, he had finally established himself with the Toronto Blue Jays, batting .321 with 15 home runs and 54 RBI and hitting a crucial solo homer in Game 5 of the American League Championship Series against the Kansas City Royals. That improbable ascent collapsed the following spring. On April 22, 2016, Major League Baseball announced that Colabello had been suspended for 80 games without pay after testing positive for a performance-enhancing substance from a March 13 urine sample. The published account does not identify the banned substance or describe a wider doping network, so the confirmed fact is the positive test and resulting suspension—not a proven conspiracy or ring. Colabello vehemently denied knowingly compromising baseball’s integrity, saying the notification was one of the most frightening calls of his life and that he had spent the intervening weeks trying to understand how the substance had entered his system. At the time, he was batting only .069, but the suspension effectively destroyed his major-league opportunity: he never appeared in another MLB game. After serving the ban, he struggled during rehabilitation and in Triple-A Buffalo, hit .180 in 40 games, cleared waivers, and subsequently bounced through minor-league organizations and overseas or independent leagues. The case remains a stark example of how an anti-doping penalty could abruptly end a player’s major-league career even when the public record contained no evidence that he had organized or participated in a broader doping operation.
Follow the sources
Status and citations are supplied by the archive. AI concept art is an interpretation, not historical evidence.